Delcath Systems, Inc.

Stage 2 · Advancing · week 22

As of Oct 22, 2026, Delcath Systems is in Stage 2, the uptrend phase, now in week 22 (since May 18, 2026). It closed at $14.75, 15.0% below its 52-week high and above its 200-day average, which is rising.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. More about the company

$14.75

+0.34% today

$512M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is DCTH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 54w

S4 23w

S2 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 3w → S4 17w → S1 10w → S2 54w → S3 7w → S2 9w → S3 3w → S4 23w → S1 6w → S4 7w → S1 3w → S2 23w current

Total tracked: 165 weeks across 12 stage runs.

DCTH among Medical Devices27th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…27	DCTHDelcath Systems, Inc.	Stage 2 · wk 22	76	−7.6%

vs 52W High

-15.0%

$8.19 lo$17.36 hi

15.0% below 52W high, deeper pullback

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 22

1w13w26w

Week 22, proven structure

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

20.7%

200 DMA: $12.22 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

1.05x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-7.6%

+20.7%

+38.6%

YTD

+48.2%

+29.6%

Scan Membership

Breakout Watch

Latest: 2025-05-23

5 appearances in last 60 days. First seen: 2020-10-02.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 22 · Vol 1.05x

2026-10-21S2

Wk 22 · Vol 0.61x

2026-10-20S2

Wk 22 · Vol 0.69x

2026-10-19S2

Wk 22 · Vol 0.68x

2026-10-16S2

Wk 22 · Vol 0.77x

2026-10-15S2

Wk 21 · Vol 0.43x

2026-10-14S2

Wk 21 · Vol 0.46x

2026-10-13S2

Wk 21 · Vol 0.49x

2026-10-12S2

Wk 21 · Vol 0.40x

2026-10-09S2

Wk 21 · Vol 0.37x

2026-10-08S2

Wk 20 · Vol 0.81x

2026-10-07S2

Wk 20 · Vol 0.50x

Moving averages & range

50 DMA

$15.96

200 DMA

$12.22

52W High

$17.36

52W Low

$8.19

5D Low

$14.08

Resistance levels (recent highs)

20d High

$15.97

60d High

$17.36

120d High

$17.36

250d High

$17.36

Next resistance

+8.3%

to 20d High

P/E (TTM)

1475.0

Forward 327.8

Earnings Growth (YoY)

0.0%

Revenue +20.6%

ROE

+0.5%

Profit margin +0.6%

Dividend Yield

0.00%

P/B 4.2

Delcath Systems: quick answers

What stage is Delcath Systems in?

As of Oct 22, 2026, Delcath Systems (DCTH) is in Stage 2, the uptrend phase. It entered Stage 2 on May 18, 2026 and is in week 22. What the four stages mean

Is Delcath Systems in an uptrend?

Yes. Delcath Systems is in a Stage 2 uptrend. It trades 20.7% above its 200-day average, which is rising.

How far is Delcath Systems from its 52-week high?

Delcath Systems closed at $14.75 on Oct 22, 2026, 15.0% below its 52-week high of $17.36. Its 52-week low is $8.19.

How has Delcath Systems performed over the past year?

As of Oct 22, 2026, Delcath Systems is up 29.6% over the past year and up 48.2% so far in 2026.

Which sector and industry is Delcath Systems in?

Delcath Systems is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.